Gilde Healthcare
VC Fund
Utrecht, The Netherlands
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
- Total investments:
- 131
- Last investment:
- Lead investor:
- 38%
- Fund size:
- $786M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Gilde Healthcare invests in
Stages Gilde Healthcare invests in
Countries Gilde Healthcare invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $9.5M–$63M
- Series B
- $15M–$135M
- Series C
- $21M–$75M
Investment Focus
Industry
- Health Care 47 (36%)
- Biotechnology 47 (36%)
- Medical 34 (26%)
- Medical Device 30 (23%)
- Pharmaceutical 17 (13%)
Stage
- Series B 25 (19%)
- Series C 21 (16%)
- Series A 18 (14%)
- Series D 14 (11%)
- Private Equity 10 (8%)
Country
- United States 26 (20%)
- The Netherlands 14 (11%)
- Germany 7 (5%)
- United Kingdom 7 (5%)
- Denmark 5 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Edwin Graaf
Managing Partner
|
Managing Partner | Total investments: 8 | Find email | |
Joep Muijrers
General Partner
|
General Partner | Total investments: 1 | Find email | |
Pieter van der Meer
Managing Partner & Founder
|
Managing Partner & Founder | Total investments: 10 | Find email | |
Stefan Luzi
Partner
|
Partner | Total investments: 2 | Find email | |
Arthur Franken
Partner
|
Partner | Total investments: 4 | Find email | |
| See all 15 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GT Medical Technologies
|
GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $100M / Series E / Jun 09, 2026 | |
Endovascular Engineering
|
Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis. | $80M / Series C / Apr 07, 2026 | |
Big Health
|
Big Health is a digital therapeutics company that operates a digital healthcare portal to offer fully-automated and highly personalized digital therapeutics and behavioral programs for mental health issues. Its portal offers an online personalized medicine-care and prepares a sleep improvement program in consultation with medical professionals thatenable individuals to overcome their sleep-related disorders in an efficient manner. | $23.7M / Venture - Series Unknown / Feb 12, 2026 | |
Sidera Bio
|
Sidera Bio harness human genetics, that helps in transformative medicines for patients. | $109M / Series A / Dec 09, 2025 | |
Okami Medical
|
Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliableregardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason.It was founded in 2011 and is headquartered in Aliso Viejo, California. | $45M / Series F / Nov 19, 2025 | |
|
Okami Medical
|
Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliableregardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason.It was founded in 2011 and is headquartered in Aliso Viejo, California. | $45M / Series F / Nov 19, 2025 | |
ProVerum Medical
|
ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. | $80M / Series B / Aug 25, 2025 | |
Splice Bio
|
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M / Series B / Jun 11, 2025 | |
Spyglass Pharma
|
Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications. | $75M / Series D / Jun 02, 2025 | |
Mobia Medical
|
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas. | $65M / Series F / Mar 12, 2025 | |
| See all 131 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gilde Healthcare invest in?
Gilde Healthcare invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 131 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Gilde Healthcare's check size?
Gilde Healthcare typically joins rounds of $9.5M–$63M at Series A, $15M–$135M at Series B and $21M–$75M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gilde Healthcare participates in.
How do I contact Gilde Healthcare?
Public channels for Gilde Healthcare include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Gilde Healthcare?
The team at Gilde Healthcare includes Edwin Graaf (Managing Partner), Joep Muijrers (General Partner) and Pieter van der Meer (Managing Partner & Founder), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
